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Objectives The aim of this study was to compare the safety and efficacy of Resolute zotarolimus-eluting stents (ZES)
(Medtronic Cardiovascular, Santa Rosa, California) with Xience V everolimus-eluting stents (EES) (Abbott Vascu-
lar Devices, Santa Clara, California) at 1-year follow-up.
Background Only 1 randomized trial previously compared these stents.
Methods This investigator-initiated, patient-blinded, randomized noninferiority study had limited exclusion criteria (acute
ST-segment elevation myocardial infarctions not eligible). Patients (n  1,391; 81.4% of eligible population)
were randomly assigned to ZES (n  697) or EES (n  694). Liberal use of stent post-dilation was encouraged.
Cardiac biomarkers were systematically assessed. The primary endpoint was target vessel failure (TVF), a com-
posite of cardiac death, myocardial infarction not clearly attributable to non-target vessels, and clinically indi-
cated target-vessel revascularization. An external independent research organization performed clinical event
adjudication (100% follow-up data available). Analysis was by intention-to-treat.
Results Acute coronary syndromes were present in 52% and “off-label” feature in 77% of patients. Of the lesions, 70%
were type B2/C; the post-dilation rate was very high (82%). In ZES and EES, TVF occurred in 8.2% and 8.1%, re-
spectively (absolute risk-difference 0.1%; 95% confidence interval: 2.8% to 3.0%, pnoninferiority  0.001). There
was no significant between-group difference in TVF components. The definite-or-probable stent thrombosis rates
were relatively low and similar for ZES and EES (0.9% and 1.2%, respectively, p  0.59). Definite stent thrombo-
sis rates were also low (0.58% and 0%, respectively, p  0.12). In EES, probable stent thrombosis beyond day 8
was observed only in patients not adhering to dual antiplatelet therapy.
Conclusions Resolute ZES were noninferior to Xience V EES in treating “real-world” patients with a vast majority of complex lesions
and “off-label” indications for drug-eluting stents, which were implanted with liberal use of post-dilation. (The Real-
World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome
After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario; NCT01066650) (J Am Coll
Cardiol 2012;59:1350–61) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.008Early trials with drug-eluting stents (DES) demonstrated a
significant reduction in restenosis and reintervention rates
(1,2), which rapidly led to the adaptation of these stents for
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April 10, 2012:1350–61 The TWENTE TrialSeveral factors and mechanisms have been suggested to be
potentially involved. A particularly important factor might be
he lack of biocompatibility of coatings on first-generation DES,
ome of which were shown to be associated with hypersensitivity
nd vessel wall inflammation that can promote stent thrombosis.
n addition, deliverability and side branch access of first-
eneration DES were somewhat limited (6), and the reduc-
ion in reintervention rates in patients with advanced coro-
ary disease was less than expected (7).
Second-generation DES with improved coatings and
designs might offer solutions to the limitations of first-
generation DES (8,9). A thin-strut, open-cell, cobalt-
chromium stent that releases everolimus from a thin
fluoropolymer-based coating (Xience V, Abbott Vascular
Devices, Santa Clara, California) has been shown to be
superior to first-generation DES, which—together with
other favorable data—led to its approval by regulatory
bodies (10). Recently, a thin-strut, cobalt-chromium, open-
cell stent that releases zotarolimus from a thin biocompat-
ible coating (Resolute, Medtronic CardioVascular, Santa
Rosa, California) showed very promising clinical results
(11–13).
More than 2 million DES are implanted annually world-
wide (14). Both everolimus-eluting Xience stents (EES)
and zotarolimus-eluting Resolute stents (ZES) represent a
substantial share of them. However, published head-to-
head comparison between both stents is limited to a single
randomized trial (15). Therefore, in the present study, we
compared safety and efficacy of the Resolute ZES with that
of the Xience V EES in a “real-world” patient population
with advanced coronary disease and complex lesions. Inter-
ventions were performed according to our routine clinical
practice, encouraging operators to make liberal use of stent
post-dilation to optimize stent apposition to the vessel wall,
which might facilitate drug delivery and could reduce stent
thrombosis (16).
Methods
Study design and patients. Between June 2008 and Au-
gust 2010, we undertook, at Thoraxcentrum Twente, Me-
disch Spectrum Twente, Enschede, the Netherlands, a
randomized noninferiority trial (the TWENTE trial) in
consecutive patients 18 years of age or older who were
capable of providing an informed consent and underwent a
PCI with DES implantation for the treatment of chronic
stable coronary artery disease or acute coronary syndromes.
To allow for the inclusion of a broad patient population, the
study protocol defined no limit for lesion length, reference
vessel size, and number of target lesions or vessels. The only
exclusion criteria were: ST-segment elevation myocardial
infarction (STEMI) or STEMI-equivalent, requiring pri-
mary or rescue PCI during the past 48 h; planned staged
revascularization; renal failure requiring hemodialysis; seri-
ous conditions that could limit the ability of the patient to
participate in study procedures, in particular life expectancy1 year; participation in investi-
gational drug or device study; or
the choice of stent type was dic-
tated by logistic reasons (e.g., a
stent with required dimensions
was only available as 1 type).
The TWENTE trial complied
with the Declaration of Helsinki
for investigation in human be-
ings and was approved by the
institutional ethics committee of
Medisch Spectrum Twente, En-
schede, the Netherlands, and the
Dutch Central Committee on
Research Involving Human Sub-
jects. All patients provided writ-
ten, informed consent for partic-
ipation in this trial.
Randomization and study de-
vices. After stratification for sex,
randomization was performed on
the basis of computer-generated random numbers (block
stratified randomization version 5.0 by S. Piantadosi), with
sealed, opaque, sequentially numbered allocation envelopes.
After passage of the guidewire or pre-dilation (if necessary),
patients were assigned in a 1:1 ratio to Resolute ZES or
Xience V EES. Patients had no knowledge of the stent type
they were allocated to (single-blinded design).
In our center, Resolute ZES were available in diameters
of 2.25, 2.50, 3.00, 3.50, and 4.00 mm. Stent length was 8
mm and 14 mm for stents with a diameter2.5 mm; 9 mm
and 15 mm for stents with a diameter of 3.00 mm; and
12, 18, 24, and 30 mm for all available stent diameters.
Xience V EES were available in diameters of 2.25, 2.50,
3.00, 3.50, and 4.00 mm and in lengths of 8, 12, 15, 18,
23, and 28 mm.
Percutaneous intervention and medication. Interventions
were performed via femoral or radial route according to
standard techniques. Complete lesion coverage was at-
tempted with 1 or more stent(s). Lesion pre-dilation, direct
stenting, and/or stent post-dilation were permitted at the
discretion of the operators. Operators were encouraged to
make liberal use of post-dilation. Although planned staging
of PCI was an exclusion criterion, unplanned staged proce-
dures were permitted if the second procedure was performed
within 6 weeks after the index procedure (e.g., in unex-
pected lengthy procedures and/or procedures with excessive
contrast use); in such cases, the allocated stent type was used
during all stages. During index procedure, mixture of stents
was not permitted unless the allocated study stent could not
be delivered; then, crossover to another stent was permitted.
Patients who were not taking acetylsalicylic acid received
300 mg of acetylsalicylic acid before PCI. In addition,
patients received before or at the time of PCI 300 to 600 mg
of clopidogrel and at least 5,000 IU or 70 to 100 IU/kg of
Abbreviations
and Acronyms
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stentunfractionated heparin, according to standard protocols.
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The TWENTE Trial April 10, 2012:1350–61Administration of glycoprotein IIb/IIIa antagonists was left
at the discretion of the operators.
In patients not receiving oral anticoagulation therapy,
we prescribed at discharge the combination of 100 mg of
acetylsalicylic acid once daily (indefinitely) and clopi-
dogrel 75 mg once daily (12 months). In patients receiv-
ing oral anticoagulation therapy, we prescribed 100 mg of
acetylsalicylic acid once daily (at least 1 month) and
clopidogrel 75 mg daily (12 months) in addition to oral
anticoagulation.
Laboratory, electrocardiographic, and angiographic anal-
yses. In all patients, the concentration of creatine kinase
was determined before PCI, and the concentration of
creatine kinase, creatine kinase-myocardial band, and tro-
ponin was measured 6 to 18 h after PCI, with subsequent serial
measurements in case of relevant biomarker elevation or
complaints. Of the cases, 97% had at least 1 blood sampling
performed between 12 and 18 h after PCI. Twelve-lead
electrocardiographs were obtained before and after PCI, before
discharge, and at suspicion of acute ischemia.
Quantitative coronary angiography was performed offline
with use of edge-detection software (QAngio XA version
7.1, Medis, Leiden, the Netherlands) by experienced ana-
lysts of Thoraxcentrum Twente, who were blinded as to the
type of study device used. All measurements (baseline and
final) were conducted according to current standards. Stan-
dard offline measurements were obtained over the entire
segment, consisting of stented segment plus 5 mm proximal
and distal margins. We defined percentage diameter steno-
sis as: ([reference vessel diameter – minimal lumen diame-
ter]/reference vessel diameter)  100%. Lesion length was
assessed, in general, by quantitative coronary angiography.
Definition of endpoints and data management. The
pre-specified primary composite endpoint was the incidence
of target vessel failure (TVF) within 1 year, defined as (in
hierarchical order) cardiac death, target vessel–related myo-
cardial infarction (MI), or clinically driven target vessel
revascularization (TVR) by re-PCI or surgery. All clinical
endpoints were defined according to the Academic Research
Consortium (17,18). Cardiac death was defined as any
death due to proximate cardiac cause (e.g., MI, low-output
failure, fatal arrhythmia), unwitnessed death and death of
unknown cause, and all procedure-related deaths, including
those related to concomitant treatment. Myocardial infarc-
tion was defined as previously outlined in detail. In brief,
MI was defined by any creatine kinase concentration of
more than double the upper limit of normal with elevated
values of a confirmatory cardiac biomarker (creatine kinase-
myocardial band fraction or troponin) (18). Moreover,
classification of MIs and location of MIs was performed on
the basis of laboratory testing, electrocardiographic param-
ters, angiographic information, and/or clinical data
17,18). A TVR was defined as any repeat coronary
evascularization (PCI or surgery) of any segment of the
ntire major coronary artery and its branches. A TVR (or
arget lesion revascularization [TLR]) was considered dclinically indicated if the angiographic percentage diam-
eter stenosis of the then-treated lesion was 50% in the
presence of ischemic signs or symptoms or if the diameter
stenosis was 70%, irrespective of ischemic signs or
symptoms (17).
Secondary endpoints were the individual components of
the primary endpoint; all-cause mortality; Q-wave and
non–Q-wave MI; any MI; TVR by PCI, surgery, or both;
clinically indicated TLR; any TLR, defined as repeated
revascularization within the stented segment including
5 mm proximal and distal border-zones; stent thrombosis,
defined according to Academic Research Consortium as
definite, probable, or possible; target lesion failure, defined
as composite of cardiac death, target vessel–related MI, and
clinically indicated TLR; major adverse cardiac events,
composite of all-cause death, any MI, emergent coronary
artery bypass surgery, or clinically indicated TLR; and a
patient-oriented composite endpoint, consisting of all-cause
mortality, any MI, and any repeat (target and non-target
vessel) revascularization. All composite endpoints, as defined in
the preceding text, are presented with the individual compo-
nents in a hierarchical order. We did not pre-specify subgroup
analyses but performed exploratory subgroup analyses in line
with the later published Resolute All Comers Trial (15).
In addition, we assessed device success, defined as
achievement of a final residual diameter stenosis 50%
uring the initial procedure, with the use of the assigned
tudy stent only; lesion success, defined as achievement of a
nal residual diameter stenosis 50% with use of any PCI
pproach; and procedure success, defined as achievement of
final residual diameter stenosis 50% together with the
bsence of any in-hospital major adverse cardiac event.
ata management and clinical event adjudication. In-
ospital adverse events were recorded before discharge. The
2-month clinical follow-up data were obtained at visits at
utpatient clinics or, if not feasible, by telephone follow-up
nd/or a medical questionnaire. For any event trigger,
embers of the study team gathered all clinical information
vailable from referring cardiologist, general practitioner,
nd/or hospital involved. If required, on-site review of the
linical chart was performed. Clinical and procedural data
ere stored in a database at Thoraxcentrum Twente. Staff
nvolved in follow-up procedures and analyses were blinded
o the assigned stent.
Processing of clinical data and adjudication of adverse
linical events were performed by an independent external
ontract research organization and core laboratory (Cardi-
lysis, Rotterdam, the Netherlands). In brief, any death,
otential MI, possible stent thrombosis, and revasculariza-
ion procedure were independently adjudicated by an exter-
al clinical event committee (blinded). In addition, Cardi-
lysis performed an on-site audit to assess key study data
nd adherence to the rules of good clinical practice. The
ocal institutional ethics committee served as independent
ata and safety monitoring board.
1353JACC Vol. 59, No. 15, 2012 von Birgelen et al.
April 10, 2012:1350–61 The TWENTE TrialStatistical analysis. The main outcome parameter of this
noninferiority study was the incidence of TVF at 1 year with
80% power to detect noninferiority at a 1-sided type I error
of 0.05. Assuming a median time to TVF of 48 months, on
the basis of the Endeavor III (Randomized Controlled Trial
of the Medtronic Endeavor Drug [ABT-578] Eluting
Coronary Stent System Versus the Cypher Sirolimus-
Eluting Coronary Stent System in De Novo Native Coro-
nary Artery Lesions) trial that had an event rate of 12.8%
(19), a hazard ratio of 1.35, an accrual time of 2 years, and
an additional follow-up of 1 year for TVF, a total of 1,380
patients was required. On the basis of the aforementioned
hazard ratio and assumed event rate, noninferiority would
Figure 1 Trial Profile
BMS  bare-metal stent(s); DES  drug-eluting stent(s); PCI  percutaneous corobe declared if the upper limit of the 1-sided 95% confidence
interval (CI) of the absolute risk difference was 4.48%.
The Newcombe-Wilson method without continuity correc-
tion was used to calculate a CI for the absolute risk
difference (20). Analyses were performed on the basis of
intention-to-treat principle. Patients were censored when
they did not reach any component of the composite primary
endpoint. Categorical variables were assessed with use of
chi-square or Fisher exact tests, as appropriate, whereas
continuous variables were assessed with the Wilcoxon rank-
sum test or Student t test, as appropriate. The time to the
primary endpoint and the components thereof were assessed
according to the method of Kaplan-Meier, and the log-rank
tervention.nary in
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The TWENTE Trial April 10, 2012:1350–61test was applied to compare the 2 groups. Kaplan-Meier
curves were drawn in accordance with guidelines provided
by Pocock et al. (21). Logistic regression was performed to
test for interaction between subgroups and stent type with
regard to the primary endpoint. A p value 0.05 was
considered significant. All p values and CIs were 2-sided,
except for those for noninferiority testing of the primary
clinical endpoint. After noninferiority was established, we
calculated regular 2-sided 95% CIs and 2-sided p values to
allow conventional interpretation of results (as for a supe-
riority design). Statistical analyses were performed with
SPSS (version 15.0, SPSS, Inc., Chicago, Illinois) and SAS
(version 9.2, SAS Institute, Inc., Cary, North Carolina).
Results
Study population. Figure 1 shows the trial profile. Patients
n  1,391; 81.4% of the eligible patient population) with
Baseline Characteristics of PatientsTable 1 Baseline Characteristics of Patients
Total Population
(n  1,391)
Age (yrs) 64.2 10.8 (1,391
Men 1,009/1,391 (72.5
BMI (kg/m2) 27.7 4.0 (1,391)
Diabetes mellitus (any) 301/1,391 (21.6
Chronic renal failure* 38/1,391 (2.7)
Arterial hypertension 773/1,391 (55.6
Hypercholesterolemia 803/1,357 (59.2
Current smoker 340/1,391 (24.4
Family history of CAD 740/1,391 (53.2
MI (any) 450/1,391 (32.4
Previous PCI 288/1,391 (20.7
Previous CABG 148/1,391 (10.6
PCI for acute coronary syndrome 717/1,391 (51.5
Clinical indication
Stable angina pectoris 674/1,391 (48.5
Unstable angina 325/1,391 (23.4
Non–ST-segment elevation MI 392/1,391 (28.2
Left ventricular ejection fraction 30%† 32/1,051 (3.0)
Multivessel treatment 336/1,391 (24.2
Total no. of lesions treated/patient
1 lesion treated 857/1,391 (61.6
2 lesions treated 393/1,391 (28.3
3 of more lesions treated 141/1,391 (10.1
De novo coronary lesions only‡ 1,287/1,391 (92.5
At least 1 CTO 95/1,391 (6.8)
At least 1 bifurcation 362/1,391 (26.0
At least 1 bifurcation with side branch treatment 213/1,391 (15.3
At least 1 in-stent restenosis 69/1,391 (5.0)
At least 1 small-vessel (RVD 2.75 mm) 874/1,391 (62.8
At least 1 lesion length 27 mm 293/1,391 (21.1
Glycoprotein IIb/IIIa antagonist use 193/1,391 (13.9
At least 1 off-label indication§ 1,077/1,391 (77.4
Values are mean  SD (n) or n/N (%). *Chronic renal failure defined by serum creatinine level 1
left ventricular angiography. ‡Including chronic total occlusion but not grafts and in-stent restenos
myocardial infarction (MI) within the previous 72 h, more than 1 lesion/vessel, at least 2 vessels wit
left main artery, lesions with thrombus, or total occlusion.BMI  body mass index; CABG  coronary artery bypass grafting; CAD  coronary artery disease; C
ntervention; RVD  reference vessel diameter; ZES  zotarolimus-eluting stent(s).,116 lesions were randomly assigned to Resolute ZES (n
97, 1,080 lesions) or Xience V EES (n  694, 1,036
esions). At least 1 allocated study stent was implanted in
89 (99%) and 690 (99%) patients allocated to Resolute
ES and Xience V EES, respectively. In each study arm, 2
0.3%) patients withdrew consent before reaching 12-
onth follow-up. In all other 1,387 patients, complete
ollow-up information was obtained (100%).
Study groups had similar baseline clinical (Table 1),
ngiographic (Table 2), and procedural characteristics (Table 3). A
otal of 52% of patients presented with an acute coronary
yndrome. Of the study population, 22% were diabetic. In a
igh proportion of patients, there was advanced coronary
isease with a need for multivessel treatment, bifurcation
esions, long lesions, and small-vessel disease. At least 1
ff-label characteristic was present in 77% of patients, and
0% of lesions were complex (type B2/C). Between study
ZES Resolute
(n  697)
EES Xience V
(n  694) p Value
63.9 10.9 (697) 64.5 10.7 (694) 0.32
505/697 (72.5) 504/694 (72.6) 0.94
27.7 3.9 (697) 27.8 4.0 (694) 0.57
158/697 (22.7) 143/694 (20.6) 0.35
19/697 (2.7) 19/694 (2.7) 0.99
386/697 (55.4) 387/694 (55.8) 0.89
392/688 (57.0) 411/669 (61.4) 0.10
176/697 (25.3) 164/694 (23.6) 0.48
370/697 (53.1) 370/694 (53.3) 0.93
213/697 (30.6) 237/694 (34.1) 0.15
139/697 (19.9) 149/694 (21.5) 0.48
68/697 (9.8) 80/694 (11.5) 0.28
362/697 (51.9) 355/694 (51.2) 0.77
0.47
335/697 (48.1) 339/694 (48.8)
172/697 (24.7) 153/694 (22.0)
190/697 (27.3) 202/694 (29.1)
19/529 (3.6) 13/522 (2.5) 0.30
174/697 (25.0) 162/694 (23.3) 0.48
0.49
422/697 (60.5) 434/694 (62.7)
198/697 (28.4) 195/694 (28.1)
77/697 (11.0) 64/694 (9.2)
644/697 (92.4) 643/694 (92.7) 0.86
51/697 (7.3) 44/694 (6.3) 0.47
179/697 (25.7) 183/694 (26.4) 0.77
98/697 (14.1) 115/694 (16.6) 0.19
36/697 (5.2) 33/694 (4.8) 0.73
445/697 (63.8) 429/694 (61.8) 0.43
156/697 (22.4) 137/694 (19.7) 0.23
90/697 (12.9) 103/694 (14.8) 0.29
547/697 (78.5) 530/694 (76.4) 0.35
l/l. †Left ventricular ejection fraction assessed with ultrasound, magnetic resonance imaging, or
label stent use includes renal insufficiency, an ejection fraction of 30%, the occurrence of acute
, a lesionmeasuringmore than 27mm, bifurcation, bypass grafts, in-stent restenosis, unprotected)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
30 mo
is. §Off-
h stentsTO  chronic total occlusion; EES  everolimus-eluting stent(s); PCI  percutaneous coronary
ciation
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April 10, 2012:1350–61 The TWENTE Trialgroups, there was no difference in the proportion of left
main stem and bypass treatment and of recanalization of
chronic total occlusions. Direct stenting was performed in
39% of lesions. In 82% of lesions, stents were post-dilated.
Primary and secondary endpoints. Table 4 shows the
major adverse cardiac events during 1-year follow-up. Tar-
get vessel failure occurred in 57 patients (8.2%) of the
Resolute ZES and in 56 patients (8.1%) of the Xience V
EES groups. We established noninferiority of the ZES with
an absolute risk difference of 0.1% (95% CI: 2.8% to
3.0%) and the upper limit of the 1-sided 95% CI of 2.53%
(1-sided p value for noninferiority 0.001) (Fig. 2A, Table 4).
Between Resolute ZES and Xience V EES groups, there
was also no difference in the components of the primary
endpoint: cardiac death (1.0% vs. 1.4%, p  0.46); target
vessel–related MI (4.6% vs. 4.6%, p  0.99); clinically
driven TVR at 12-month follow-up (3.3% vs. 2.7%, p 
0.54) (Figs. 2B to 2D, Table 4).
In addition, there was no difference between groups in
other secondary endpoints (Table 4), such as the incidence
of death from any cause (2.2% vs. 2.0%, p  0.86).
The results of an exploratory subgroup analysis of the
primary endpoint are shown in Figure 3. This analysis
suggested a potential interaction between stent type and
diabetes mellitus (p  0.045) with a trend toward a lower
Baseline Lesion CharacteristicsTable 2 Baseline Lesion Characteristics
Total Lesions
(n  2,116)
Target lesion coronary artery
Left main 54 (2.6)
Left anterior descending 878 (41.5)
Left circumflex 483 (22.8)
Right coronary artery 653 (30.9)
Bypass graft 48 (2.3)
ACC/AHA lesion class
A 154 (7.3)
B1 478 (22.6)
B2 678 (32.0)
C 806 (38.1)
De novo lesions* 1,999 (94.5)
Chronic total occlusion 100 (4.7)
In stent restenosis 75 (3.5)
Aorta ostial lesion 154 (7.3)
Severe calcification 364 (17.2)
Bifurcated lesion 518 (24.5)
Thrombus present† 71 (3.4)
Total occlusion 203 (9.6)
Pre-procedural TIMI flow grade
0 120 (5.7)
1 83 (3.9)
2 140 (6.6)
3 1,773 (83.8)
Values are n (%). *Including chronic total occlusion but not grafts and in
ACC American College of Cardiology; AHA American Heart Asso
in Table 1.rate of TVF in diabetic patients treated with EES (13.9%[22 of 158] vs. 7.7% [11 of 143], p  0.08; relative risk:
1.81 [95% CI: 0.91 to 3.60] for Resolute ZES and Xience V
EES, respectively). In nondiabetic patients, TVF did not
differ significantly between stent types (6.5% [35 of 539] vs.
8.2% [45 of 551], p 0.29; relative risk: 0.80 [95% CI: 0.52
to 1.22] for Resolute ZES and Xience V EES, respectively).
Stent thrombosis. Definite or probable stent thrombosis
occurred in 6 patients (0.9%) of the Resolute ZES group (1
death, 4 MI, 1 repeat TVR) and 8 patients (1.2%) of the
Xience V EES group (4 death, 4 MI) (p  0.59) (Fig. 4,
Table 4). In the EES arm, probable stent thrombosis
beyond day 8 was only observed in patients not adhering to
dual antiplatelet therapy (stent thromboses on day 28 and
day 136) (Fig. 4). The incidence of definite stent thrombosis
was low in both study arms. It occurred in 4 patients (0.6%)
of the Resolute ZES arm and in none (0%) of the Xience V
EES arm (p  0.12) (Fig. 4, Table 4). One patient (day
245) was not receiving dual antiplatelet therapy. Three of 4
patients with definite stent thrombosis (75%) survived this
event. The only fatal event (day 5) occurred in a patient
enrolled for stenting of right and left anterior descending
arteries, 7 days after treatment of the circumflex artery with a
bare metal stent for a large, subacute non-STEMI. Autopsy
revealed thrombus formation and/or coagulated blood in all 3
vessels, and the event was classified as definite stent thrombo-
S Resolute
,080 Lesions)
EES Xience V
(n  1,036 Lesions) p Value
26 (2.4) 28 (2.7) 0.67
441 (40.8) 437 (42.2) 0.53
243 (22.5) 240 (23.2) 0.72
349 (32.3) 304 (29.3) 0.13
21 (1.9) 27 (2.6) 0.38
0.90
77 (7.1) 77(7.5)
241 (22.3) 237 (22.9)
342 (31.7) 336 (32.4)
420 (38.9) 386 (37.3)
024 (94.8) 975 (94.1) 0.48
53 (4.9) 47 (4.5) 0.69
38 (3.5) 37 (3.6) 0.95
76 (7.1) 78 (7.6) 0.66
192 (17.8) 172 (16.6) 0.47
258 (23.9) 260 (25.1) 0.52
33 (3.1) 38 (3.7) 0.43
109 (10.1) 94 (9.1) 0.43
0.82
63 (5.8) 57 (5.5)
46 (4.3) 37 (3.6)
73 (6.8) 67 (6.5)
898 (83.1) 875 (84.5)
estenosis. †Thrombus triggering use of thrombus aspiration catheters.
; TIMI Thrombolysis In Myocardial Infarction; other abbreviations asZE
(n  1
1,
-stent rsis, according to the definition.
in-hosp
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In this randomized trial, which comprised a vast majority of
patients with “off-label” indication for DES (77%), the
Resolute ZES group and the Xience V EES group had a
similar incidence of the primary composite endpoint of
TVF at 12-month follow-up. As a result, the Resolute ZES
met the criterion of noninferiority versus the Xience V EES.
In addition, between both study groups there was no
significant difference in the individual components of the
primary endpoint (cardiac death, target vessel–related MI,
and clinically indicated TVR).
In the present study, more than 80% of all eligible
patients were enrolled. There were only a few exclusion
criteria. As a consequence, the majority of patients of this
“real-world” patient population were treated in a nonelective
setting, and a high proportion of patients had complex
lesions and suffered from advanced coronary disease, which
required multivessel PCI.
More than one-half of the patients of our study presented
with acute coronary syndromes, whereas primary PCI for
acute STEMI was an exclusion criterion. Nevertheless,
most other patient and lesion characteristics and procedural
details were similar to the few previous comparative stent
studies in “all comers” populations (varying STEMI pro-
portion of 12% to 25%) (15,22,23). Although the implan-
tation of DES for treatment of STEMI has gained accep-
tance (24), this approach was not the standard when the
Quantitative Coronary Angiography and Procedural ResultsTable 3 Quantitative Coronary Angiography and Procedural Res
Total Lesions
(n  2,116)
Lesion length (mm) 14.43 (9.80–22.09)
Diameter of reference vessel (mm) 2.65 (2.29–3.06)
Baseline minimum lumen diameter (mm) 0.99 (0.72–1.29)
Baseline stenosis, lumen diameter (%) 61.92 (52.74–71.20)
Post-procedure stenosis, lumen diameter (%) 11.84 (9.05–15.34)
Post-procedure minimum lumen diameter (mm) 2.27 (1.89–2.67)
Acute gain in segment (mm) 1.25 (0.86–1.68)
Stents implanted
Per patient 2.02 1.18
Per lesion 1.33 0.62
Total stent length (mm)
Per patient 40.97 26.86
Per lesion 26.9 15.69
Direct stenting 824 (38.9)
Post-dilation 1,727 (81.6)
Maximal stent diameter/lesion (mm) 2.97 (0.46)
Implantation of study stent only 2,094 (99.0)
Device success* 2,074 (98.0)
Lesion success† 2,112 (99.8)
Procedure success‡ 1,332/1,391 (95.8)
Values are median (interquartile range), mean  SD, n (%), or n/N (%). *Device success is defined
study device. †Lesion success is defined as the attainment at the target site of a final residual diam
at the target site of a final residual diameter stenosis of 50%, together with the absence of any
Abbreviations as in Table 1.present study was designed.To date, there is only 1 other published trial (Resolute All
Comers) (15) with a head-to-head comparison of the same
stents as in the present study. That trial assessed 1,140
patients in the Resolute ZES arm and 1,152 patients in the
EES arm and demonstrated noninferiority of the ZES in a
patient population with minimal exclusion criteria. This was
confirmed by the present trial.
The clinical event adjudication of both the Resolute All
Comers and TWENTE trial was performed by the same
independent clinical research organization, which might
facilitate meaningful comparison of clinical outcome data.
In the TWENTE trial, the incidence of TVF (8.2% and
8.1%, respectively) was lower than in the Resolute All
Comers study (9.0% and 9.6%, respectively). This was the
result of lower clinically indicated TVR rates (3.3% and
2.7% vs. 3.9% and 3.4%) and slightly lower rates of cardiac
death (1.0% and 1.4% vs. 1.3% and 1.7%), whereas the rates
of target vessel–related MI were slightly higher in the
TWENTE trial (4.6% and 4.6% vs. 4.2% and 4.1%).
The majority of target vessel–related MIs occur during
the periprocedural period. Therefore, the high rate of stent
post-dilation in the present trial (82% of lesions) might
explain the slightly higher rate of target vessel–related MIs
compared with the Resolute All Comers study (15). By
contrast, stent post-dilation is likely to improve stent apposi-
tion and drug delivery, which might have contributed to the
somewhat lower rate of clinically indicated TVR in the present
study. In fact, this rate was even lower than that of EES in the
ZES Resolute
(n  1,080 Lesions)
EES Xience V
(n  1,036 Lesions) p Value
14.51 (9.85–22.54) 14.30 (9.66–21.83) 0.35
2.65 (2.30–3.05) 2.66 (2.28–3.07) 0.73
0.97 (0.72–1.29) 1.00 (0.73–1.29) 0.39
62.57 (52.78–71.34) 61.26 (52.67–71.07) 0.31
11.67 (8.93–14.90) 12.00 (9.18–15.64) 0.07
2.29 (1.89–2.69) 2.25 (1.88–2.65) 0.37
1.24 (0.89–1.70) 1.25 (0.83–1.65) 0.22
2.03 1.19 2.02 1.18 0.91
1.31 0.59 1.35 0.64 0.09
41.84 27.66 40.09 26.02 0.22
27.00 15.39 26.85 16.00 0.83
416 (38.5) 408 (39.4) 0.68
876 (81.1) 848 (82.1) 0.54
2.96 (0.452) 2.98 (0.468) 0.37
1,068 (98.9) 1,026 (99.0) 0.74
1,063 (98.4) 1,011 (97.6) 0.17
1,078 (99.8) 1,034 (99.8) 0.97
667/697 (95.7) 665/694 (95.8) 0.91
attainment at the target site of a final residual diameter stenosis of 50% with only the assigned
enosis of50% with any percutaneous method. ‡Procedure success is defined as the attainment
ital major adverse cardiac events.ults
as the
eter stSPIRIT IV (Clinical Evaluation of the XIENCE V Everoli-
use de
bbrevia
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center trial that compared EES and paclitaxel-eluting stents in
2,485 and 1,229 patients, respectively (14).
In the TWENTE trial, direct stenting was performed in
39% of lesions. This is similar to the rate of direct stenting
in other trials with complex lesions (30% to 40%)
(15,22,23). Further mechanistically oriented data analyses of
interventional techniques and assessment of their potential
relation with clinical outcome will help to define the impact
of pre- and post-dilation on the results of the present trial.
Intuitively, one might tend to argue that the lack of
inclusion of patients with STEMI in the TWENTE trial
might have contributed to a low rate of TVF. However, in
the Resolute All Comers trial, the 12% STEMI patients
actually had lower rates of TVF and fewer major cardiac
1-Year Clinical Outcomes in the Intention-to-Treat Study PopulationTable 4 1-Year Clinical Outcomes in the Intention-to-Treat Stud
Total Population
(n  1,387)
Target vessel failure 113 (8.1)
Death
Any cause 29 (2.1)
Cardiac cause 17 (1.2)
Target vessel-related MI
Any 64 (4.6)
Q-wave 11 (0.8)
Non–Q-wave 53 (3.8)
Periprocedural MI 57 (4.1)
Clinically indicated TVR
Any 42 (3.0)
Percutaneous 33 (2.4)
Surgical 9 (0.6)
Target lesion failure 102 (7.4)
Clinically indicated TLR
Any 29 (2.1)
Percutaneous 22 (1.6)
Surgical 7 (0.5)
Death from cardiac causes or target vessel MI 67 (4.8)
Major adverse cardiac events* 132 (9.5)
Patient-oriented composite endpoint† 151 (10.9)
Definite ST (0–360 days)
All patients 4 (0.3)
Acute (0–1 day) 0 (0)
Subacute (2–30 days) 1 (0.1)
Late (31–360 days) 3 (0.2)
Probable ST (0–360 days)
All patients 10 (0.7)
Acute (0–1 day) 4 (0.3)
Subacute (2–30 days) 4 (0.3)
Late (31–360 days) 2 (0.1)
ST (0–360 days)
Possible 6 (0.4)
Definite or probable 14 (1.0)
Definite, probable, or possible 20 (1.4)
Values are n (%). *Major adverse cardiac events are a composite of all-cause death, any myo
revascularization (TLR). †Patient-oriented composite endpoint is a composite of endpoint of all-ca
CI  confidence interval; TVR  target vessel revascularization; ST  stent thrombosis; other aevents than the overall study population (25). This mightpartly be explained by the difficulty of identifying
periprocedural MI in the setting of STEMI (18). In
addition, because of the generally reduced myocardial
mass subtended, restenoses of infarct-related arteries are
less likely to provoke myocardial ischemia, which can
have a lowering effect on the TVR rate. In the
COMPARE (Trial of Everolimus-eluting Stents and
Paclitaxel-eluting Stents for Coronary Revascularization
in Daily Practice), which assessed 897 patients treated
with EES and 903 patients treated with paclitaxel-
eluting stents, clinically justified TVR in the EES arm
(2.1%) (22) was even lower than in the Resolute All
Comers study (15) and in the present study. For reasons
discussed in the preceding text, the particularly high
proportion of STEMI in the COMPARE trial (27%)
pulation
Resolute
 695)
EES Xience V
(n  692)
Difference
(95% CI) p Value
(8.2) 56 (8.1) 0.1 (2.8 to 3.0) 0.94
(2.2) 14 (2.0) 0.1 (1.3 to 1.6) 0.86
(1.0) 10 (1.4) 0.4 (1.6 to 0.7) 0.46
(4.6) 32 (4.6) 0.0 (2.2 to 2.2) 0.99
(0.7) 6 (0.9) 0.1 (1.1 to 0.8) 0.76
(3.9) 26 (3.8) 0.1 (1.9 to 2.1) 0.90
(4.2) 28 (4.0) 0.1 (2.0 to 2.2) 0.91
(3.3) 19 (2.7) 0.6 (1.2 to 2.4) 0.54
(2.7) 14 (2.0) 0.7 (0.9 to 2.3) 0.39
(0.6) 5 (0.7) 0.1 (1.0 to 0.7) 0.73
(7.9) 47 (6.8) 1.1 (1.6 to 3.9) 0.42
(2.7) 10 (1.4) 1.3 (0.2 to 2.8) 0.09
(2.2) 7 (1.0) 1.1 (0.2 to 2.5) 0.09
(0.6) 3 (0.4) 0.1 (0.6 to 0.9) 0.71
(4.9) 33 (4.8) 0.1 (2.1 to 2.4) 0.92
(10.1) 62 (9.0) 1.1 (2.0 to 4.2) 0.48
(11.2) 73 (10.5) 0.7 (2.6 to 4.0) 0.69
(0.6) 0 (0) 0.6 (0.0 to 1.1) 0.12
(0) 0 (0) — —
(0.1) 0 (0) 0.1 (0.1 to 0.4) 1.00
(0.4) 0 (0) 0.4 (0.0 to 0.9) 0.25
(0.3) 8 (1.2) 0.9 (1.8 to 0.0) 0.06
(0.1) 3 (0.4) 0.3 (0.9 to 0.3) 0.37
(0.0) 4 (0.6) 0.6 (1.1 to 0.0) 0.06
(0.1) 1 (0.1) 0.0 (0.4 to 0.4) 1.00
(0.6) 2 (0.3) 0.3 (0.4 to 1.0) 0.69
(0.9) 8 (1.2) 0.3 (1.3 to 0.8) 0.59
(1.4) 10 (1.4) 0.0 (1.3 to 1.3) 0.99
l infarction (MI), emergent coronary artery bypass surgery, or clinically indicated target lesion
ath, any MI, or any revascularization.
tions as in Table 1.y Po
ZES
(n
57
15
7
32
5
27
29
23
19
4
55
19
15
4
34
70
78
4
0
1
3
2
1
0
1
4
6
10
cardiamight have contributed to this difference (22).
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The TWENTE Trial April 10, 2012:1350–61In the exploratory subgroup analysis of the primary
endpoint, there was no difference in TVF across all different
subgroups except for diabetes mellitus, which showed a
significant interaction with the type of stent (p  0.045),
indicating a trend in diabetic patients toward a lower rate of
TVF in the EES arm (p  0.08). Although this finding is
ntriguing, it should be considered at most as hypothesis-
enerating. Undoubtedly, it is desirable to perform further
asic and clinical research on DES in the field of diabetes
ellitus (26,27).
Our study was not statistically powered to prove potential
ifferences in stent thrombosis, but there are several findings
hat are worth discussion. In the TWENTE trial, the
ncidence of definite stent thrombosis tended to be lower
han in the Resolute All Comers trial (relative risk: 0.4; p 
.09). In the Resolute ZES arm of the current trial, both the
ates of definite as well as definite or probable stent
hrombosis (0.6% and 0.9%, respectively) were low and
Figure 2 Kaplan-Meier for Primary Endpoint and the Individual C
Kaplan-Meier cumulative incidence curves at 1 year for the primary endpoint, a co
revascularization (A); cardiac death (B); myocardial infarction (C); and target-vess
eluting Xience V stent.ne-half as high as in the Resolute All Comers trial (1.2% snd 1.6%, respectively) (15). In addition, we did not see any
lustering of definite or probable stent thrombosis in Res-
lute ZES in the acute or early subacute phase, as has
reviously been described (15). One patient with definite
tent thrombosis on day 245 was not receiving dual anti-
latelet therapy because of an intolerance to acetylsalicylic
cid. In addition, the only fatal definite stent thrombosis
ccurred in a patient in whom sudden death (on day 5 after
ndex procedure and day 12 after non-STEMI, respectively)
ould have been caused by fatal post-infarction arrhythmias.
ther trials have previously shown a relatively low risk of
tent thrombosis in Resolute ZES; in the RESOLUTE US
Clinical evaluation of the Resolute zotarolimus-eluting
oronary stent system in the treatment of de novo lesions in
ative coronary arteries), ISAR-TEST 5 (Intracoronary
tenting and Angiographic Results: Test Efficacy of
irolimus- and Probucol-Eluting Versus Zotarolimus-
luting Stents), and Resolute All Comers trials, definite
onents of the Primary Endpoint
e of cardiac death, target-vessel related myocardial infarction, or target-vessel
scularization (D) for the zotarolimus-eluting Resolute stent and the everolimus-omp
mposit
el revatent thrombosis rates ranged from 0.1% to 1.2% (12,13,15).
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April 10, 2012:1350–61 The TWENTE TrialIn the present study, the Xience V EES arm showed no
definite stent thrombosis at 1-year follow-up. The
TWENTE trial is the first randomized trial that showed no
definite stent thrombosis in a complex “real-world” patient
population with advanced coronary disease and challenging
lesions. The use of EES has previously been associated with
a relatively low risk of stent thrombosis (28). In the SPIRIT
III and IV, COMPARE, and Resolute All Comers trials,
definite stent thrombosis rates in EES ranged from 0.3% to
0.8% (10,15,22,29). In contrast to the absence of definite
stent thrombosis in the Xience V study arm of the
TWENTE trial, there were 8 adverse cardiac events that
were adjudicated as probable stent thromboses—4 of them
being lethal. However, beyond 8 days after the index
procedure, none of these probably thrombotic events oc-
Figure 3 Subgroup Analysis: Target Vessel Failure at 1 Year
Target vessel failure is a composite of cardiac death, target-vessel myocardial infa
between stent type and presence of diabetes mellitus; interaction testing was not
ment elevation myocardial infarction; PCI  percutaneous coronary intervention.curred in a patient who adhered to dual antiplatelet therapy(the events on day 28 and day 136 occurred in patients not
receiving dual antiplatelet therapy) (Fig. 4).
The strengths of the present study are the assessment
of a “real-world” patient population with advanced dis-
ease and complex lesions, enrollment of more than 80%
of all eligible patients, systematic post-procedural mea-
surement of cardiac biomarkers (available in 99% of
patients), absence of loss to follow-up, and verification of
all patient-reported clinical event triggers from the
source. We also consider the entirely clinical endpoint as
a strength, because angiographic assessment of a sub-
group of patients— even if performed after the 12-month
clinical endpoint has been reached (e.g., angiographic
assessment at 13 months)— could have an impact on the
important 2-year clinical outcome data of the TWENTE
, or clinically driven target vessel revascularization. *p  0.045 for interaction
cant for all other subgroups. CI  confidence interval; NSTEMI  non–ST-seg-rction
signifipopulation.
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The TWENTE Trial April 10, 2012:1350–61Study limitations. This trial was performed in a high-
volume tertiary center for PCI by 5 experienced operators
with relatively uniform procedural strategies and liberal use
of stent post-dilation; therefore, generalization of the results
might be limited in other settings. The results of the
TWENTE trial might not apply to patients with acute
STEMI, because they were not studied in this trial. In
addition, we did not pre-specify subgroup analysis; however,
to avoid a subjective post hoc selection, we used the same
subgroups as the Resolute All Comers trial (15).
Conclusions
Resolute ZES were noninferior to Xience V EES in terms of
safety and efficacy for treating “real-world” patients with a vast
majority of complex lesions and “off-label” indications for
DES, which were implanted with liberal use of post-dilation.
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